RxDoctor Payments Data

Steven Rozak, MD

Internal Medicine · Auburn, MANPI 1154302065

Payments from drug & device makers

$7,853in general payments, 2019–2025

Across 462 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Boehringer Ingelheim$826
  • Pfizer$723
  • Johnson & Johnson$542
  • Novo Nordisk$538
  • Teva Pharmaceuticals USA, Inc.$497
  • plus $3K from 23 others

What the payments were for

  • Food & beverage$7,849100%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,853 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$34,481
Medicare patients
228
Services billed
549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban123$95,129
OzempicSemaglutide31$28,827
XareltoRivaroxaban24$26,860
TrulicityDulaglutide26$26,391
JanuviaSitagliptin Phosphate27$24,559
JardianceEmpagliflozin21$21,728
Breo ElliptaFluticasone/Vilanterol21$11,434
Atorvastatin Calcium403$8,354
Testosterone34$8,177
Arnuity ElliptaFluticasone Furoate12$4,370
Rosuvastatin Calcium78$3,335
Albuterol Sulfate HfaAlbuterol Sulfate61$2,347
Colchicine18$1,825
Ezetimibe24$1,771
Pantoprazole Sodium133$1,734

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$723$96,558139 claims
Novo NordiskOzempic$538$28,82731 claims
Johnson & JohnsonXarelto$542$26,86024 claims
Lilly USA, LLCTrulicity$496$26,39126 claims
MerckJanuvia$342$24,55927 claims
Boehringer IngelheimJardiance$826$21,72821 claims
GSKBreo Ellipta, Arnuity Ellipta$333$15,80533 claims
AbbVieSynthroid$259$1,05926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Auburn

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →